Effective as of January 1, 2014, Ronnda Bartel, will step down from her role as the Chief Scientific Officer of Aastrom Biosciences, Inc. Dr. Bartel will continue as a consultant.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
48.5 USD | -1.84% |
|
+3.90% | +36.20% |
Jun. 20 | TD Cowen Initiates Vericel at Buy With $55 Price Target | MT |
Jun. 14 | Vericel Insider Sold Shares Worth $1,526,350, According to a Recent SEC Filing | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.20% | 2.36B | |
+6.96% | 101B | |
+8.29% | 42.63B | |
-11.09% | 33.5B | |
+82.32% | 29.77B | |
-11.82% | 16.14B | |
+1.39% | 14.31B | |
-12.13% | 11.55B | |
+176.65% | 10.53B | |
+6.74% | 9.2B |
- Stock Market
- Equities
- VCEL Stock
- News Vericel Corporation
- Aastrom Biosciences, Inc. Announces Resignation of Ronnda Bartel as Chief Scientific Officer